Veru (VERU) Stock Price, News & Analysis

Company Overview

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $3.20 to $3.63
• 50-Day Range: $3.17 to $6.95
• 52-Week Range: $2.64 to $14.20
• Volume: 197,052 shs
• Average Volume: 275,694 shs
• Market Capitalization: $53.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.33
• Consensus Rating: Buy

Veru Stock Analysis - MarketRank™

Veru scored higher than 51% of companies evaluated by MarketBeat, and ranked 544th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Veru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Veru has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Veru are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veru is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veru is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Veru has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.98% of the float of Veru has been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Veru has recently decreased by 88.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veru does not currently pay a dividend.

Dividend Growth

Veru does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.98% of the float of Veru has been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Veru has recently decreased by 88.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.36

News Sentiment

Veru has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Veru this week, compared to 2 articles on an average week.

Search Interest

13 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.

MarketBeat Follows

9 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Veru insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERU Stock Analysis - Frequently Asked Questions

How have VERU shares performed this year?

Veru's stock was trading at $6.5050 at the start of the year. Since then, VERU shares have decreased by 44.3% and is now trading at $3.6250.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) posted its earnings results on Tuesday, August, 12th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05.
Read the conference call transcript.

When did Veru's stock split?

Veru's stock reverse split on Monday, August 11th 2025.The 1-10 reverse split was announced on Wednesday, August 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Veru's major shareholders?

Top institutional investors of Veru include MPM Bioimpact LLC (33.51%), Geode Capital Management LLC (1.10%), Envestnet Asset Management Inc. (0.42%) and 180 Wealth Advisors LLC (0.31%). Insiders that own company stock include Mitchell Shuster Steiner, Harry Fisch, Michael L Rankowitz and K Gary Barnette.
View institutional ownership trends.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Ford Motor (F), Walt Disney (DIS) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/20/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Personal Products
• Current Symbol: NASDAQ:VERU
• CIK: 863894
• Web: www.veruhealthcare.com
• Phone: (305) 509-6897
• Fax: 312-595-9122
• Employees: 230
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Veru: $33.33
• High Price Target: $50.00
• Low Price Target: $20.00
• Potential Upside/Downside: +928.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.80 million
• Net Margins: N/A
• Pretax Margin: -410.86%
• Return on Equity: -143.24%
• Return on Assets: -85.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.42
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: $16.89 million
• Price / Sales: 2.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 3.09

Miscellaneous

• Outstanding Shares: 14,660,000
• Free Float: 12,430,000
• Market Cap: $47.50 million
• Optionable: Optionable
• Beta: -0.72